Pharmacokinetic Study of Carboplatin Given on a 5-Day Intravenous Schedule
-
- ANDO Yuichi
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- MINAMI Hironobu
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- SAKA Hideo
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- ANDO Masahiko
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SUGIURA Seiji
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SAKAI Shuzo
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SHIMOKATA Kaoru
- First Department of Internal Medicine, Nagoya University School of Medicine
Search this Article
Author(s)
-
- ANDO Yuichi
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- MINAMI Hironobu
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- SAKA Hideo
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- ANDO Masahiko
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SUGIURA Seiji
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SAKAI Shuzo
- Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital
-
- SHIMOKATA Kaoru
- First Department of Internal Medicine, Nagoya University School of Medicine
Journal
-
- Jpn J Cancer Res
-
Jpn J Cancer Res 88(5), 517-521, 1997-05-31
References: 19
-
1
- Carboplatin dosage:prospective evaluation of a simple formula based on renal function
-
CALVERT AH
J Clin Oncol 7, 1748-1756, 1989
Cited by (25)
-
2
- Phase I clinical and pharmacologic trial of carboplatin daily for 5 days
-
VAN ECHO D. A.
Cancer Treat. Rep. 68, 1103-1114, 1984
Cited by (1)
-
3
- Phase I study of carboplatin given on a five-day intravenous schedule
-
ROZENCWEIG M.
J. Clin. Oncol. 1, 621-626, 1983
Cited by (2)
-
4
- Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose
-
DAUGAARD G.
Cancer Chemother. Pharmacol. 21, 163-167, 1988
Cited by (1)
-
5
- Pharmacokinetics of carboplatin at a dose of 750 mg m^<-2> divided over three consecutive days
-
MULDER P. O. M.
Br. J. Cancer 61, 460-464, 1990
Cited by (1)
-
6
- <no title>
-
ARMITAGE P.
Statistical Methods in Medical Research, 195-206, 1994
Cited by (1)
-
7
- Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma
-
REECE P. A.
Cancer Chemother. Pharmacol. 19, 326-330, 1987
Cited by (1)
-
8
- Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation?
-
SORENSEN B. T.
Eur. J. Cancer 29, S110, 1993
Cited by (1)
-
9
- <no title>
-
HARTLAND SJ.
Cancer Res. 44, 1693-1697, 1984
Cited by (6)
-
10
- Parmacokinetics and dosage of cisdiammine- ( 1, 1- cyclobutanedicarboxylato)platinum in patients with impaired renal function
-
EGORIN MJ.
Cancer Res 44, 5432-5438, 1984
Cited by (10)
-
11
- Response of nude mouse-grown human urothelial cancer to cis-diamminedichloroplatinum(II), diammine[1, 1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride
-
KYRIAZIS A. P.
Cancer Res. 45, 2012-2015, 1985
Cited by (1)
-
12
- Response of nude mouse-grown adenocarcinomas of the human exocrine pancreas to cis-diamminedichloroplatinum(II), diammine[1, 1-cyclobutanedicarboxylato(2-)-O, O'-platinum], and mitoguazone dihydrochloride
-
KYRIAZIS A. P.
Cancer Res. 45, 4354-4359, 1985
Cited by (1)
-
13
- Estimation of variance for harmonic mean half-lives
-
LAM F. C.
J. Pharm. Sci. 74, 229-231, 1985
Cited by (2)
-
14
- The two-period cross-over clinical trial
-
HILLS M.
Br J Clin Pharmacol 8, 7-20, 1979
Cited by (4)
-
15
- <no title>
-
SHEINER L. B.
J. Pharmacokinet. Biopharm. 9, 503-512, 1981
DOI Cited by (30)
-
16
- Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination
-
VAN WARMERDAM L. J. C.
Cancer Chemother. Pharmacol. 35, 179-181, 1994
Cited by (1)
-
17
- A limited sampling method for estimation of the carboplatin area under the curve
-
SORENSEN B. T.
Cancer Chemother Pharmacol 31, 324-327, 1993
Cited by (2)
-
18
- A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer
-
CHATELUT E.
Cancer Chemother. Pharmacol. 35, 391-396, 1995
Cited by (1)
-
19
- Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
-
WARMERDAM van L. J. C.
Cancer Chemother Parmacol 37, 226-270, 1996
Cited by (2)
Cited by: 1
-
1
- Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer
-
SHIMOKATA Tomoya , ANDO Yuichi , YASUDA Yoshinari , HAMADA Akinobu , KAWADA Kenji , SAITO Hideyuki , MATSUO Seiichi , KONDO Masashi , IMAIZUMI Kazuyoshi , HASEGAWA Yoshinori
Cancer science 101(12), 2601-2605, 2010-12-10
Ichushi Web References (23)